Back

Single Versus Repeated Intravenous Oncolytic Virus Infusions: Implications for Rationalised Scheduling of Therapy in Hepatocellular Carcinoma.

2024-09-27 oncology Title + abstract only
View on medRxiv
Show abstract

Scheduling of oncolytic virus (OV) therapy has never been correlated with immunological /clinical response. In hepatocellular carcinoma (HCC) patients, where background liver is frequently chronically injured, repeated dosing may have deleterious implications, resulting in off-target immune-mediated damage, thereby tipping the balance between favourable clinical response and hepatotoxicity. Elucidation of the optimum dosing regime is paramount to ensure therapy, whilst limiting damage to backgro...

Predicted journal destinations